Therapy for Ocular Toxoplasmosis

REFERENCES

• Arevalo JF, Belfort R, Muccioli C, Espinoza JV. Ocular toxoplasmosis in the developing world. Int Ophthalmol Clin. 2010;50(2):57–69.
   PubMedGoogle Scholar
• de-la-Torre A, López-Castillo CA, Rueda JC, Mantilla RD, Gómez-Marín JE, Anaya JM. Clinical patterns of uveitis in two ophthalmology centres in Bogota, Colombia. Clin Exp Ophthalmol. 2009 Jul;37(5):458–466.
   PubMed Web of Science ®Google Scholar
• Holland G, Lewis K. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 2002;134(6):102–114.
   PubMed Web of Science ®Google Scholar
• Lum F, Jones JL, Holland GN, Liesegang TJ. Survey of ophthalmologists about ocular toxoplasmosis. Am J Ophthalmol. 2005;140:724–726.
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Harden M, Stanford M. Antibiotics versus control for toxoplasma retinochoroiditis. Cochrane Database Systematic Rev. 2002, Issue 1. Art. No.: CD002218. DOI: 10.1002/14651858.CD002218.
   Google Scholar
• Vedula SS, Nguyen QD. Corticosteroidsfor ocular toxoplasmosis. Cochrane Database Systematic Rev. 2008, Issue 4. Art. No.: CD007417. DOI: 10.1002/14651858.CD007417.
   Google Scholar
• Silveira C, Belfort R, Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002;134(1):41–46.
   PubMed Web of Science ®Google Scholar
• Acers TE. Toxoplasmicretinochoroiditis: a double-blind therapeutic study. Arch Ophthalmol. 1964;71:58–62.
   PubMed Web of Science ®Google Scholar
• Belfort R, Muccioli C, Silveira C. Trimetoprim and sulfametoxazol for the prevention of toxoplasmicretinochoroiditis recurrences. Invest Ophthalmol Vis Sci. 2000;41:595.
   Web of Science ®Google Scholar
• Perkins ES, Smith CH, Schoeld PB. Treatment of uveitis withpyrimethamine (Daraprim). Br J Ophthalmol. 1956;40:577–586.
   PubMedGoogle Scholar
• Gilbert RE, Freeman K, Lago EG, et al.; The European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). Ocular Sequelae of Congenital Toxoplasmosis in Brazil Compared with Europe. PLoSNeglTropDis 2008;2:e277.
   Google Scholar
• Gallego C, Saavedra-Matiz C, Gómez-Marín JE. Direct genotyping of animal and human isolates of Toxoplasma gondii from Colombia (South America). Acta Tropica. 2006,97:161–167.
   PubMed Web of Science ®Google Scholar
• Garweg JG, Ventura AC, Halberstadt M, et al. Specific antibody levels in the aqueous humor and serum of two distinct populations of patients with ocular toxoplasmosis. Int J Med Microbiol. 2005;295(4):287–295.
   PubMed Web of Science ®Google Scholar
• Sauer A, de la Torre A, Gomez-Marin J, Bourcier T, Garweg J, Speeg-Schatz C, Candolfi E. Prevention of retinochoroiditis in congenital toxoplasmosis: Europe versus South America. Pediatr Infect Dis J. 2011;30:601–603.
   PubMed Web of Science ®Google Scholar
• Stanford MR, Gilbert RE. Treating ocular toxoplasmosis: current evidence. Mem Inst Oswaldo Cruz. 2009;104(2):312–315.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118(1):134–141. Epub 2010 Aug 12.
   PubMed Web of Science ®Google Scholar
• Lasave AF, Díaz-Llopis M, Muccioli C, Belfort R Jr, Arevalo JF. Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmicretinochoroiditis at twenty-four months. Ophthalmology. 2010;117(9):1831–1838. Epub 2010 May 14.
   PubMed Web of Science ®Google Scholar
• Winterhalter S, Severing K, Stammen J, Maier AK, Godehardt E, Joussen AM. Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis? Graefes Arch Clin Exp Ophthalmol. 2010 Aug;248(8):1187–1192. Epub 2010 May 2.
   PubMed Web of Science ®Google Scholar
• Yazici A, Ozdal PC, Taskintuna I, Kavuncu S, Koklu G. Trimethoprim/sulfamethoxazole and azithromycin combination therapy for ocular toxoplasmosis. Ocul Immunol Inflamm. 2009 Jul–Aug;17(4):289–291.
   PubMed Web of Science ®Google Scholar
• The SYROCOT Study Group, Thiebaut R, Leproust S, Chene G, Gilbert RE. Effectiveness of prenatal treatment for congenital toxoplasmosis: a metaanalysis of individual patients’ data. Lancet. 2007;369:115–122.
   PubMed Web of Science ®Google Scholar
• Kieffer F, Wallon M, Garcia P, Thulliez P, Peyron F, Franck J. Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis. Pediatr Infect Dis J. 2008;27:27–32.
   PubMed Web of Science ®Google Scholar
• Freeman K, Tan HK, Prusa A, et al. ; European Multicentre Study on Congenital Toxoplasmosis. Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study. Pediatrics. 2008;121(5):e1215–e1222.
   Web of Science ®Google Scholar
• Phan L, Kasza K, Jalbrzikowski J, et al. Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol. 2008;146:375–384.
   PubMed Web of Science ®Google Scholar
• Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics. 2004;113(6):1567–1572.
   PubMed Web of Science ®Google Scholar
• Lahmar I, Guinard M, Sauer A, et al. Murine neonatal infection provides an efficient model for congenital ocular toxoplasmosis. Exp Parasitol. 2010;124:190–196.
   PubMed Web of Science ®Google Scholar
• Andrade GM, Vasconcelos-Santos DV, Carellos EV, et al. Congenital toxoplasmosis from a chronically infected woman with reactivation of retinochoroiditis during pregnancy. J Pediatr (Rio J). 2010;86:85–88.
   PubMed Web of Science ®Google Scholar
• Peters PJ, Thigpen MC, Parise ME, Newman RD. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf. 2007;30:481–501.
   PubMed Web of Science ®Google Scholar
• Rothova A, Meenken C, Buitenhuis HJ, et al. Therapy for ocular toxoplasmosis. Am J Ophthalmol. 1993;115:517–523.
   PubMed Web of Science ®Google Scholar
• de-la-Torre A, Rios-Cadavid AC, Cardozo-García CM, Gomez-Marín JE. Frequency and factors associated with recurrences of ocular toxoplasmosis in a referral centre in Colombia. Br J Ophthalmol. 2009;93:1001–1004.
   PubMed Web of Science ®Google Scholar
• McLeod R, Kieffer F, Sautter M, Hosten T, Pelloux H. Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz. 2009;104:320–344.
   PubMed Web of Science ®Google Scholar
• Holland GN, Engstrom R, Glasgow BJ, et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1988;106:653–667.
   PubMed Web of Science ®Google Scholar
• Elkins BS, Holland GN, Opremcak EM, et al. Ocular toxoplasmosis misdiagnosed as cytomegalovirus retinopathy in immunocompromised patients. Ophthalmology. 1994;101:499–507.
   PubMed Web of Science ®Google Scholar
• Cochereau-Massin I, Le-Hoang P, Lautier-Frau M, et al. Ocular toxoplasmosis in human immunodeficiency virus infected patients. Am J Ophthalmol. 1992;114:130–135.
   PubMed Web of Science ®Google Scholar
• Gagliuso DJ, Teich SA, Friedman AH, Orellana J. Ocular toxoplasmosis in AIDS patients. Trans Am Ophthalmol Soc. 1990;88:63–86.
   PubMedGoogle Scholar
• Huskinson-Mark J, Araujo FG, Remington JS. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis. 1991;164:170–171.
   PubMed Web of Science ®Google Scholar
• Pearson PA, Piracha AR, Sen HA, Jaffe GJ. Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology. 1999;106:148–153.
   PubMed Web of Science ®Google Scholar
• Lopez JS, De Smet MD, Masur H, et al. Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1992;113(3):331–333.
   PubMed Web of Science ®Google Scholar
• Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, et al. A prospective, randomized trial of pyrimethamine and azithromycin vspyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;134(1):34–40.
   PubMed Web of Science ®Google Scholar
• Silveira C, Vallochi AL, Rodrigues da Silva U, et al. Toxoplasma gondii in the peripheral blood of patients with acute and chronic toxoplasmosis. Br J Ophthalmol. 2011;95(3):396–400.
   PubMed Web of Science ®Google Scholar
• O’Connor GR, Frenkel JK. [Editorial] Dangers of steroid treatment in toxoplasmosis: periocular injections and systemic therapy. Arch Ophthalmol. 1976;94 (2):213.
   PubMedGoogle Scholar
• Sabates R, Pruett RC, Brockhurst RJ. Fulminant ocular toxoplasmosis. Am J Ophthalmol. 1981;92:497–503.
   PubMed Web of Science ®Google Scholar
• Dorangeon PH, Marx-Chemla C, Quereux C, et al. [The risks of pyrimethamine-sulfadoxine combination in the prenataltreatment of toxoplasmosis]. J Gynecol Obstet Biol Reprod (Paris). 1992;21:549–556.
   PubMedGoogle Scholar
• Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. 2005;11:1876–1882.
   Google Scholar
• Kishore K, Conway MD, Peyman GA. Intravitreal clindamycin and dexamethasone for toxoplasmicretinochoroiditis. Ophthalmic Surg Lasers. 2001;32(3):183–192.
   PubMedGoogle Scholar
• Fichera ME, Bhopale MK, Roos DS. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother. 1995;39:1530–1537.
   PubMed Web of Science ®Google Scholar
• Peyman GA, Lee PJ, Seal D. Endophthalmitis Diagnosis and Management. London: Taylor & Francis; 2004: 81–100.
   Google Scholar
• Miro JM, Lopez JC, Podzamczer D, et al. GESIDA 04/98 Study Group.Discontinuation of primary and secondary Toxoplasma gondiiprophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis. 2006;43(1):79–89.
   PubMed Web of Science ®Google Scholar